Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In Switzerland detailed individual patient data are lacking on trends in health care costs, major drivers of costs, and the contribution of breakthrough innovations, such as direct-acting agents (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection in people with HIV (PWH).
Methods: We linked anonymized data of patients undergoing antiretroviral therapy (ART) or naive patients initiating ART between 2012 and 2017 in the Swiss HIV Cohort Study with claims data of health insurers covering 35% of Swiss residents. Trends in mean annual costs for overall care, ART, and hospitalizations were calculated with an adjustment of costs for censoring. Changes in costs over time in relation to patient characteristics, comorbidities, and treatment of HCV with DAAs were estimated by linear mixed models. Costs were reported in Swiss francs (CHF).
Results: The final linked file contained 1830 individuals from 11 286 participants of the Swiss HIV Cohort Study and 5406 claims records (33.9%). The mean adjusted annual overall cost in 2012 was CHF 24 713 (SD, 14 107) and increased in 2017 by 1.2% to CHF 24 881 (SD, 14 523). Costs for ART contributed by far most to overall costs but decreased over time. Mean costs for hospitalizations increased with annual variation by 7.2% from CHF 8727 (SD, 10 473) in 2012 to CHF 9406 (SD, 9696) in 2017. Mean increases of costs for DAAs for 171 PWH coinfected with HCV (9.4%) were CHF 52 647 (95% CI, 50 862-54 431; < .01).
Conclusions: Increases in mean total costs for PWH in Switzerland from 2012 to 2017 were small. The contribution of DAAs for the treatment of chronic HCV to overall costs was marginal.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314359 | PMC |
| http://dx.doi.org/10.1093/ofid/ofaf410 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of the national HIV pre-exposure prophylaxis (PrEP) programme among female sex workers in Rwanda: a retrospective cohort study.
Sex Transm Infect
September 2025
Division of Clinical Epidemiology, University Hospital Basel and University of Basel, Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
Background: In 2018, Rwanda incorporated oral pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine (Truvada) into national HIV guidelines as part of a comprehensive HIV prevention programme for female sex workers (FSWs). This study assessed the impact of PrEP on HIV incidence among FSWs in urban Rwanda.
Methods: We conducted a retrospective cohort study among HIV-negative FSWs aged≥18 years at 20 health facilities in Kigali from January 2019 to October 2021.
Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIV.
mBio
August 2025
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zürich, Switzerland.
Improved biomarkers for predicting progression to active tuberculosis (TB) are urgently needed, especially in people with HIV, who are at elevated risk. We used high-throughput plasma proteomics and machine learning to identify signatures associated with TB progression in this population. From the Swiss HIV Cohort Study, we analyzed plasma samples collected at least 6 months before TB diagnosis from 91 participants who later developed TB.
View Article and Find Full Text PDFExploring the Diversity and Distribution of Medico-Veterinary Fungal Diseases in Africa: Harnessing a Multisectoral One Health Strategy for Cost-Effective Prevention and Preparedness.
J Fungi (Basel)
July 2025
Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum 11111, Sudan.
The diversity and distribution of medical and veterinary-relevant fungal diseases in Africa underscore the critical need for a multisectoral One Health strategy to enhance cost-effective preparedness and prevention. This review explores the geographic spread and epidemiology of key medical and veterinary fungi, including , , , , , , , , , , and . Evidence indicates that many of these infections remain underdiagnosed and underreported, especially in vulnerable immunocompromised populations, due to limited surveillance, diagnostic capacity, and awareness.
View Article and Find Full Text PDFCost and Budget Impact of Layering Depression Care Onto Existing HIV and Noncommunicable Disease Care Services in Western Kenya.
Value Health Reg Issues
August 2025
Center for Global Public Health, Brown University School of Public Health, RI, USA; Academic Model Providing Access to Healthcare, Eldoret, Kenya; Department of Health Services, Policy and Practice, Brown University School of Public Health, RI, USA.
Objectives: The World Health Organization Mental Health Action Plan aims to increase mental healthcare coverage by half, by 2030. Reaching this target requires context-specific financial assessments. We estimated the cost and budget impact of integrating depression care into HIV, diabetes, and hypertension care programs in county-level health facilities in Kenya.
View Article and Find Full Text PDFUntargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study.
J Infect Dis
August 2025
University Department of Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel, Bruderholz, Switzerland.
Background: Obesity is a major concern in people with HIV (PWH). How obesity and antiretroviral therapy (ART) are associated with specific metabolite profiles in PWH is not well described.
Methods: We included Swiss HIV Cohort Study participants aged ≥45 years.